Steven Annen Buys 5,000 Shares of FocalTherics (NASDAQ:FOCL) Stock

FocalTherics (NASDAQ:FOCL) SVP Steven Annen bought 5,000 shares of FocalTherics stock in a transaction that occurred on Friday, August 14th. The shares were acquired at an average price of $4.75 per share, for a total transaction of $23,750.00. Following the acquisition, the senior vice president directly owned 136,490 shares in the company, valued at approximately $648,327.50. This represents a 3.80% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

FocalTherics Trading Down 2.3%

Shares of NASDAQ FOCL opened at $4.26 on Wednesday. FocalTherics has a 12-month low of $1.30 and a 12-month high of $6.40. The firm has a market cap of $159.66 million, a P/E ratio of -4.14 and a beta of -0.04. The company has a current ratio of 1.34, a quick ratio of 0.99 and a debt-to-equity ratio of 1.79. The firm has a fifty day moving average of $5.38.

FocalTherics (NASDAQ:FOCL) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.19). The company had revenue of $13.20 million during the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. On average, sell-side analysts forecast that FocalTherics will post -0.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Leonteq Securities AG acquired a new stake in FocalTherics during the 4th quarter valued at approximately $313,000. Kovack Advisors Inc. acquired a new position in shares of FocalTherics in the 4th quarter valued at approximately $53,000. Rock Springs Capital Management LP boosted its stake in shares of FocalTherics by 1.3% during the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock valued at $4,233,000 after buying an additional 16,500 shares during the last quarter. Flax Pond Capital LLC purchased a new position in shares of FocalTherics during the 4th quarter valued at approximately $2,623,000. Finally, SmartHarvest Portfolios LLC acquired a new stake in shares of FocalTherics during the first quarter worth approximately $38,000. Hedge funds and other institutional investors own 62.74% of the company’s stock.

Trending Headlines about FocalTherics

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: FocalTherics insiders collectively purchased 116,000 shares for approximately $551,000 at $4.75 per share. Buyers included CEO Ryan Rhodes, CFO Kenneth Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and several directors. The coordinated open-market purchases may signal that company leadership views recent weakness as an attractive entry point. FocalTherics insider buying report
• Positive Sentiment: Director Lance Willsey made the largest purchase at 50,000 shares, while CEO Ryan Rhodes bought 21,000 shares. Other executives and directors increased their holdings by roughly 2.8% to 196%, strengthening the insider-buying signal. FocalTherics director transaction filing
• Neutral Sentiment: Recent filings show several institutional investors initiated positions, and institutions collectively own 62.74% of FocalTherics. While this indicates continued professional-investor interest, the disclosed purchases vary considerably in size and do not establish a clear near-term catalyst.
• Neutral Sentiment: A recent article characterized FocalTherics as targeting market leadership following a “record-breaking quarter,” but the available report provides insufficient financial detail to independently assess the claim. FocalTherics market leadership article
• Negative Sentiment: The company’s latest quarterly loss was $0.39 per share, substantially worse than the expected $0.20 loss, on revenue of $13.20 million. FocalTherics also reported a negative net margin of 56.26% and analysts expect a full-year loss of approximately $0.78 per share, keeping profitability and financing risk in focus.
• Negative Sentiment: Analyst opinion is mixed: although some firms maintain Buy or Outperform ratings and a $7.75 consensus target, Piper Sandler rates the stock Neutral with a $4 target, while Wall Street Zen recently downgraded it to Sell. Shares also remain below their 50-day moving average of $5.38, reflecting continued technical weakness.

Wall Street Analyst Weigh In

Several equities analysts recently commented on FOCL shares. Piper Sandler reissued a “neutral” rating and set a $4.00 price target on shares of FocalTherics in a research report on Friday. Mizuho set a $15.00 price objective on shares of FocalTherics and gave the company an “outperform” rating in a research note on Friday, July 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of FocalTherics in a research report on Monday. Wall Street Zen downgraded shares of FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of FocalTherics in a report on Tuesday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $7.75.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.